Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy

Atherosclerosis

Volumn 221, Issue 1, 2012, Pages 160-168

  Bellanger, Natacha ^a,b   Julia, Zélie ^a,b   Villard, Elise F ^a,b   El Khoury, Petra ^a,b   Duchene, Emilie ^a,b   Chapman, M John ^a,b   Fournier, Natalie ^c,d   Le Goff, Wilfried ^a,b   Guerin, Maryse ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c EA 4529   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Cellular cholesterol efflux; CETP; HDL CE uptake; High density lipoprotein

Indexed keywords

ABC TRANSPORTER G1; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SCAVENGER RECEPTOR BI; TORCETRAPIB; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; HUMAN; HYPERLIPIDEMIA; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIVER CELL; MALE; PARTICLE SIZE; POSTPRANDIAL STATE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANIMALS; ANTIGENS, CD36; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; ATP-BINDING CASSETTE TRANSPORTERS; CHO CELLS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; CRICETINAE; CRICETULUS; DRUG THERAPY, COMBINATION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, HDL2; LIVER; MACROPHAGES; MALE; MICE; MIDDLE AGED; PARIS; PARTICLE SIZE; POSTPRANDIAL PERIOD; PYRROLES; QUINOLINES; TIME FACTORS; TRANSFECTION; TREATMENT OUTCOME;

EID: 84857034980     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.12.027     Document Type: Article

References (35)

1. Bansal S., Buring J.E., Rifai N., et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298:309-316.
2. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308.
3. Kolovou G.D., Anagnostopoulou K.K., Pavlidis A.N., et al. Postprandial lipemia in men with metabolic syndrome, hypertensives and healthy subjects. Lipids Health Dis 2005, 4:21.
4. Basciano H., Federico L., Adeli K. Fructose, insulin resistance, and metabolic dyslipidemia. Nutr Metab (Lond) 2005, 2:5.
5. Lairon D., Lopez-Miranda J., Williams C. Methodology for studying postprandial lipid metabolism. Eur J Clin Nutr 2007, 61:1145-1161.
6. Castro G.R., Fielding C.J. Effects of postprandial lipemia on plasma cholesterol metabolism. J Clin Invest 1985, 75:874-882.
7. Guerin M., Egger P., Soudant C., et al. Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the postprandial state. J Lipid Res 2002, 43:1652-1660.
8. Julia Z., Duchene E., Fournier N., et al. Postprandial lipemia enhances the capacity of large HDL2 particles to mediate free cholesterol efflux via SR-BI and ABCG1 pathways in type IIB hyperlipidemia. J Lipid Res 2010, 51:3350-3358.
9. Lassel T.S., Guerin M., Auboiron S., Chapman M.J., Guy-Grand B. Preferential cholesteryl ester acceptors among triglyceride-rich lipoproteins during alimentary lipemia in normolipidemic subjects. Arterioscler Thromb Vasc Biol 1998, 18:65-74.
10. Syeda F., Senault C., Delplanque B., et al. Postprandial variations in the cholesteryl ester transfer protein activity, phospholipid transfer protein activity and plasma cholesterol efflux capacity in normolipidemic men. Nutr Metab Cardiovasc Dis 2003, 13:28-36.
11. Tall A., Granot E., Brocia R., et al. Accelerated transfer of cholesteryl esters in dyslipidemic plasma. Role of cholesteryl ester transfer protein. J Clin Invest 1987, 79:1217-1225.
12. Chapman M.J., Le Goff W., Guerin M., Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 2010, 31:149-164.
13. Catalano G., Julia Z., Frisdal E., et al. Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway. Arterioscler Thromb Vasc Biol 2009, 29:268-275.
14. Yvan-Charvet L., Matsuura F., Wang N., et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 2007, 27:1132-1138.
15. Guerin M., Egger P., Le Goff W., et al. Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia. J Clin Endocrinol Metab 2002, 87:4991-5000.
16. Catalano G., Duchene E., Julia Z., et al. Cellular SR-BI and ABCA1-mediated cholesterol efflux are gender-specific in healthy subjects. J Lipid Res 2008, 49:635-643.
17. Miyazaki O., Kobayashi J., Fukamachi I., et al. A new sandwich enzyme immunoassay for measurement of plasma pre-beta1-HDL levels. J Lipid Res 2000, 41:2083-2088.
18. Larrede S., Quinn C.M., Jessup W., et al. Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent. Arterioscler Thromb Vasc Biol 2009, 29:1930-1936.
19. Bellanger N., Orsoni A., Julia Z., et al. Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2011, 31:1675-1681.
20. Guerin M., Le Goff W., Duchene E., et al. Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia. Arterioscler Thromb Vasc Biol 2008, 28:148-154.
21. Kuivenhoven J.A., de Knijff P., Boer J.M., et al. Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels. Arterioscler Thromb Vasc Biol 1997, 17:560-568.
22. Kolovou G., Anagnostopoulou K., Kostakou P., et al. Association between the TaqIB polymorphism in the cholesteryl ester transfer protein gene locus and postprandial plasma lipoprotein levels in heterozygotes for familial hypercholesterolemia. Clin Chem Lab Med 2007, 45:1190-1198.
23. Fournier N., de la Llera Moya M., Burkey B.F., et al. Role of HDL phospholipid in efflux of cell cholesterol to whole serum: studies with human apoA-I transgenic rats. J Lipid Res 1996, 37:1704-1711.
24. Fournier N., Atger V., Cogny A., et al. Analysis of the relationship between triglyceridemia and HDL-phospholipid concentrations: consequences on the efflux capacity of serum in the Fu5AH system. Atherosclerosis 2001, 157:315-323.
25. Jian B., de la Llera-Moya M., Royer L., et al. Modification of the cholesterol efflux properties of human serum by enrichment with phospholipid. J Lipid Res 1997, 38:734-744.
26. Greene D.J., Skeggs J.W., Morton R.E. Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI). J Biol Chem 2001, 276:4804-4811.
27. Vergeer M., Korporaal S.J., Franssen R., et al. Genetic variant of the scavenger receptor BI in humans. N Engl J Med 2011, 364:136-145.
28. Brousseau M.E., Diffenderfer M.R., Millar J.S., et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 2005, 25:1057-1064.
29. Davidson W.S., Lund-Katz S., Johnson W.J., et al. The influence of apolipoprotein structure on the efflux of cellular free cholesterol to high density lipoprotein. J Biol Chem 1994, 269:22975-22982.
30. Lottin H., Motta C., Simard G. Differential effects of glycero- and sphingo-phospholipolysis on human high-density lipoprotein fluidity. Biochim Biophys Acta 1996, 1301:127-132.
31. Fournier N., Paul J.L., Atger V., et al. HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscler Thromb Vasc Biol 1997, 17:2685-2691.
32. Schlitt A., Hojjati M.R., von Gizycki H., et al. Serum sphingomyelin levels are related to the clearance of postprandial remnant-like particles. J Lipid Res 2005, 46:196-200.
33. Miller N.E., Nanjee M.N. Evidence that reverse cholesterol transport is stimulated by lipolysis of triglyceride-rich lipoproteins. FEBS Lett 1991, 285:132-134.
34. Tall A.R., Krumholz S., Olivecrona T., Deckelbaum R.J. Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. J Lipid Res 1985, 26:842-851.
35. Nilsson A., Duan R.D. Absorption and lipoprotein transport of sphingomyelin. J Lipid Res 2006, 47:154-171.